Group

Immunoassays play a pivotal role in oncology, from cancer screening and diagnosis to therapeutic drug monitoring. The technology is primarily used to detect and quantify cancer biomarkers, which are substances produced by cancer cells or by the body in response to cancer. These biomarkers, such as PSA for prostate cancer or CA-125 for ovarian cancer, are crucial for the early detection of the disease and for monitoring a patient's response to treatment. The market for oncology-related immunoassays is a high-growth segment, driven by the increasing incidence of cancer worldwide and a growing emphasis on personalized medicine. Furthermore, immunoassays are vital in the development and monitoring of targeted cancer therapies. They are used to measure the levels of therapeutic drugs in a patient's blood to ensure they are within the optimal range, a process known as therapeutic drug monitoring (TDM). The precision and sensitivity of immunoassays are essential for these applications, as the concentration of biomarkers and drugs can be very low. The continuous discovery of new cancer biomarkers and the development of more effective targeted therapies ensure that the use of immunoassays in oncology will only expand in the future. For an in-depth analysis of these applications and the market's oncology segment, you can refer to the comprehensive Immunoassay Market report.